Diroximel Fumarate

Diroximel Fumarate (CAS No.: 1577222-14-0) is a synthetic small molecule and orally bioavailable prodrug scaffold used in biomedical research as a monomethyl fumarate precursor, primarily categorized within immunometabolism and redox biology research for studies of fumarate mediated signaling, electrophile responsive transcriptional control, and inflammation associated cellular stress adaptation; current mechanistic understanding indicates rapid biotransformation to monomethyl fumarate with downstream engagement of the Nrf2 antioxidant response axis, modulation of KEAP1 linked redox sensing, and broader effects on cytokine associated inflammatory pathways and cellular resilience programs, while target level characterization in discovery settings is generally interpreted through pathway readouts rather than a single high affinity receptor interaction, and published preclinical literature for this molecular class commonly reports pathway modulation and functional phenotypes across nanomolar to micromolar concentration ranges depending on assay design, exposure duration, and matrix context; accordingly, this compound is widely positioned for use in mechanistic cell based assays, oxidative stress and neuroinflammation relevant model systems, and translational pharmacology workflows including comparative prodrug evaluation, biomarker driven pathway profiling, and candidate benchmarking against related fumarate derivatives, with concentrations or doses used in experiments typically depending on specific experimental designs and research objectives, and with interpretation appropriately confined to nonclinical research use in controlled laboratory settings.